Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26699713 | 0.92 | CA1 (0.38) | CA1CA2 | |
| SCHEMBL16583639 | 0.90 | TSHR (0.33) | KAT2BBAZ2BTSHRSMN1; SMN2 | |
| SCHEMBL707230 | 0.86 | LRRK2 (0.31) | — | |
| SCHEMBL709288 | 0.86 | LRRK2 (0.31) | — | |
| SCHEMBL707231 | 0.86 | LRRK2 (0.31) | — | |
| SCHEMBL2099337 | 0.82 | — | — | |
| SCHEMBL4334769 | 0.82 | CA1 (0.40) | CA1CA2TSHR | |
| SCHEMBL18604421 | 0.79 | — | — | |
| SCHEMBL3826761 | 0.78 | GPR119 (0.31) | — | |
| SCHEMBL2566376 | 0.77 | CA1 (0.31) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 777 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070048-A1 | NITROGEN-CONTAINING BRANCHED POLYMER, ANION EXCHANGE MEMBRANE, AND METHOD FOR PREPARING ANION EXCHANGE RESIN | EVE HYDROGEN ENERGY CO LTD (CN) | 2026-03-12 | — | — | US | claimed |
| US-20250243320-A1 | SULFONATE GROUP-BASED ANION RESIN, PREPARATION METHOD THEREOF, AND ANION EXCHANGE MEMBRANE | EVE Hydrogen Energy Co., LTD. (CN) | 2025-07-31 | — | — | US | claimed |
| US-20250243308-A1 | NITROGEN-CONTAINING MULTICOMPONENT COPOLYMER, MANUFACTURING METHOD THEREOF, ANIONIC RESIN, AND ANION EXCHANGE MEMBRANE | EVE Hydrogen Energy Co., LTD. (CN) | 2025-07-31 | — | — | US | claimed |
| EP-4591970-A1 | NITROGEN-CONTAINING MULTICOMPONENT COPOLYMER, MANUFACTURING METHOD THEREOF, ANIONIC RESIN, AND ANION EXCHANGE MEMBRANE | EVE Hydrogen Energy Co., LTD. (CN) | 2025-07-30 | — | — | EP | claimed |
| EP-4591978-A1 | SULFONATE GROUP-BASED ANION RESIN, PREPARATION METHOD THEREOF, AND ANION EXCHANGE MEMBRANE | EVE Hydrogen Energy Co., LTD. (CN) | 2025-07-30 | — | — | EP | claimed |
| CN-119930958-A | Anion exchange polymer and preparation method thereof, and preparation method of anion exchange membrane | 惠州亿纬氢能有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119264352-A | Nitrogen-containing branched polymer, anion exchange resin, anion exchange membrane and electrochemical device | 惠州亿纬氢能有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-115458809-B | Electrolyte and lithium ion battery comprising same | 湖州昆仑亿恩科电池材料有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118027359-A | Nitrogen-containing compound, preparation method thereof, anion resin and anion exchange membrane | 惠州亿纬氢能有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117924628-A | Method for producing sulfonic anion resin, and anion exchange membrane | 惠州亿纬氢能有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117924629-A | Nitrogen-containing multipolymer, preparation method thereof, anion resin and anion exchange membrane | 惠州亿纬氢能有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-115458809-A | Electrolyte and lithium ion battery comprising same | 香河昆仑新能源材料股份有限公司 | 2022-12-09 | — | — | CN | claimed |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | disclosed |
| US-20260138986-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORP (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137698-A1 | CYCLIN-DEPENDENT KINASE 7 INHIBITORS | JOINT STOCK CO «BIOCAD» (RU) | 2026-05-21 | — | — | US | disclosed |
| EP-1220856-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-0994875-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999000385-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070048-A1 | NITROGEN-CONTAINING BRANCHED POLYMER, ANION EXCHANGE MEMBRANE, AND METHOD FOR PREPARING ANION EXCHANGE RESIN | SLC9A2, SLC9A3, SLC9B2 | CA1 4415/4885CA2 3456/4885KAT2B 4435/4885 |
| US-20260137698-A1 | CYCLIN-DEPENDENT KINASE 7 INHIBITORS | CDK7, CDK6, CDK3 | CA1 2214/4885CA2 1631/4885KAT2B 273/4885 |
| US-20260138986-A1 | PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | KIT, PDGFRA, PDGFRB | CA1 2489/4885CA2 1736/4885KAT2B 2558/4885 |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX7 | CA1 3871/4885CA2 546/4885KAT2B 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.